Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Long QT syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    49 result(s) found for: Long QT syndrome. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-000042-30 Sponsor Protocol Number: GS-US-372-1234 Start Date*: 2015-05-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome
    Medical condition: Subjects with an established diagnosis of LQT3.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10024803 Long QT syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000564-28 Sponsor Protocol Number: IIBSP-QTL-2017-96 Start Date*: 2018-05-23
    Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau - IIB Sant Pau
    Full Title: Genetic characterization of drug-induced Long QT Syndrome
    Medical condition: Drug-induced Long QT Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000250-94 Sponsor Protocol Number: MAST2 Start Date*: 2020-07-17
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Mutation-specific therapy for the long QT syndrome
    Medical condition: Long QT syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10057926 Long QT syndrome congenital PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003958-86 Sponsor Protocol Number: GS-US-356-5413 Start Date*: 2022-06-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Study of Females Exposed to Eleclazine
    Medical condition: The goal of this study is to follow up with female subjects who received eleclazine in prior clinical trials for ischemic heart disease, ventricular arrhythmia, hypertrophic cardiomyopathy or long ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10055218 Ischemic heart disease LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10007541 - Cardiac disorders 10024803 Long QT syndrome PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-005082-47 Sponsor Protocol Number: HUS/1209/2017 Start Date*: 2018-09-24
    Sponsor Name:Sydän- ja keuhkokeskus, HUS
    Full Title: Repolarization study in LQTS patients
    Medical condition: Long QT syndrome (LQTS) is a hereditary arrhythmia disease. It causes disturbances to the ion flow through cell membranes of cardiomyocytes. These disturbances can sometimes seen in an electrocardi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001244-26 Sponsor Protocol Number: COV-2-SOLNATIDE-20 Start Date*: 2020-04-11
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria
    Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.
    Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002874-19 Sponsor Protocol Number: 63935937MDS3001 Start Date*: 2015-11-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Sti...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003855-47 Sponsor Protocol Number: AP301-II-002 Start Date*: 2018-02-27
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability oedema in patients with moderate-to-severe ARDS - a randomised, placebo-controlle...
    Medical condition: pulmonary permeability oedema in patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005547-17 Sponsor Protocol Number: RHMNUT0048 Start Date*: 2010-01-28
    Sponsor Name:Southampton University Hospital NHS Trust
    Full Title: Refeeding risks in patients requiring nutrition support. A twin centre double-blind randomised controlled trial of parenteral nutrition support.
    Medical condition: Patients who have a non-functioning gastrointestinal tract require artifical intravenous nutrition. This is usally a result recent surgery or sepsis causing a reversible short term paralysis of th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004310-19 Sponsor Protocol Number: W00090GE303/EORTC-2139-MG Start Date*: 2022-02-15
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group
    Medical condition: Resected BRAF V600E/K stage IIB/C melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Completed) AT (Completed) NL (Completed) PL (Completed) GR (Completed) CZ (Completed) HU (Completed) ES (Ongoing) PT (Prematurely Ended) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004021-25 Sponsor Protocol Number: IM026-024 Start Date*: 2021-10-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus.
    Medical condition: Active Systemic Lupus Erythematosus.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001888-23 Sponsor Protocol Number: TV7820-CNS-20002 Start Date*: 2014-03-25
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus...
    Medical condition: Huntington’s disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) AT (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000399-13 Sponsor Protocol Number: Uni-Koeln-3254 Start Date*: 2019-03-08
    Sponsor Name:University of Cologne
    Full Title: A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harbouring FGFR genetic alterations after relapse of standard therapy
    Medical condition: •Stage IIIB/IV NSCLC patients with activating FGFR alteration after the failure of ≥ 1st line standard therapy •Activating FGFR alteration as defined by FIND Molecular Board •ECOG performance sta...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000430-11 Sponsor Protocol Number: RFBU11-I Start Date*: 2011-10-06
    Sponsor Name:G.I.S.E. - SOCIETA'' ITALIANA CARDIOLOGIA INVASIVA
    Full Title: Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX)
    Medical condition: Real world ACS both Non-ST segment elevation and ST-segment elevation patients undergoing coronary angiography±PCI.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing) SE (Ongoing) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000441-38 Sponsor Protocol Number: CPCRA 065 Start Date*: 2005-04-26
    Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
    Medical condition: HIV infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002935-27 Sponsor Protocol Number: ADVL1712 Start Date*: 2021-05-21
    Sponsor Name:National Cancer Institute
    Full Title: A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute...
    Medical condition: This trial studies the side effects and how well pevonedistat, azacitidine, fludarabine phosphate, and cytarabine work in treating patients with acute myeloid leukemia that has come back or has not...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024330 Leukemia acute LLT
    21.0 100000004864 10024349 Leukemia myeloid LLT
    21.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-004967-21 Sponsor Protocol Number: ET743-OVC-1001 Start Date*: 2008-10-20
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
    Medical condition: - to assess the potential effects of trabectedin on the QT/QTc interval duration measured by electrocardiograms (ECGs) in subjects with advanced solid tumor malignancies when administered at a ther...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007050 Cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:48:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA